TY - JOUR T1 -服用葡萄糖胺与肺癌风险的关系:数据从一个全国性的前瞻性群组研究摩根富林明——欧洲呼吸杂志乔——欧元和J - 10.1183/13993003.01399 -2021 SP - 2101399 AU - Li必要非盟-张,徐汇盟——刘Yingxin盟——张Junguo AU - Li Likang盟——黄,鑫盟——撒贝恩Lehana盟,嘴唇,葡萄糖胺的研究表明，抗炎和抗癌的好处和最小的副作用。我们的目的是基于大规模英国生物银行前瞻性队列研究的数据，探讨葡萄糖胺的使用与肺癌风险和肺癌死亡率之间的关系。方法在2006年至2010年期间招募参与者，并随访至2020年。采用Cox比例危害模型评估葡萄糖胺的使用与肺癌风险和肺癌死亡率的关系。进行亚组分析和敏感性分析，以探讨潜在的影响修改和主要发现的稳健性。结果共439393名参与者(平均年龄56岁;(53%女性)，平均随访11年。有82603名(18.80%)参与者报告在基线时定期服用葡萄糖胺。在随访期间，记录了1,971例(0.45%)肺癌事件。在完全调整的模型中，服用葡萄糖胺与肺癌风险(风险比=0.84,95% CI: 0.75-0.92, p=0.002;0.001)和肺癌死亡率(风险比=0.88,95% CI: 0.81-0.96, p=0.002)的降低显著相关。 A stronger association between glucosamine use and decreased lung cancer risk was observed in participants with a family history of lung cancer when compared to those without a family history.Conclusion Regular use of glucosamine was significantly related with decreased risk of lung cancer and lung cancer mortality, based on data from this nationwide prospective cohort study.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. li has nothing to disclose.Conflict of interest: Dr. Zhang has nothing to disclose.Conflict of interest: Dr. Liu has nothing to disclose.Conflict of interest: Dr. Zhang has nothing to disclose.Conflict of interest: Dr. Li has nothing to disclose.Conflict of interest: Dr. Huang has nothing to disclose.Conflict of interest: Dr. Thabane has nothing to disclose.Conflict of interest: Dr. Lip reports other from Novartis, Bayer/Janssen, Biotronik, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Verseon, and Daiichi-Sankyo, other from Medtronic, Bayer, BMS/Pfizer, Boehringer Ingelheim, and Daiichi-Sankyo, outside the submitted work; . ER -